PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 116.60 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-20
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 159.02K shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 75.00K shares, a 19.35% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-06-30 was 404.54K shares, a 102.27% increase year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 30.62K shares, a 93.87% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 116.60K shares, a 847.97% increase from fiscal 2024.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 12.30K shares, a 98.16% decline from fiscal 2023.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 669.18K shares, a 4121.42% increase from fiscal 2022.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 15.85K shares, a 98.70% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 116.60K shares 10-K · filed 2026-03-20 | |||
| 2024-12-31 | 12.30K shares 10-K · filed 2025-03-24 | |||
| 2023-12-31 | 159.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 234.02K shares derived: sum of 2 quarters · filed 2024-03-26 | 638.56K shares derived: sum of 3 quarters · filed 2024-03-26 | 669.18K shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 75.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 479.54K shares derived: sum of 2 quarters · filed 2023-11-09 | 510.16K shares 10-Q · filed 2023-11-09 | -266.59K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 404.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 435.16K shares 10-Q · filed 2023-08-10 | -341.59K shares derived: sum of 3 quarters · filed 2023-08-10 | -248.59K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 30.62K shares 10-Q · filed 2023-05-11 | -746.13K shares derived: sum of 2 quarters · filed 2023-05-11 | -653.13K shares derived: sum of 3 quarters · filed 2023-05-11 | -453.13K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | -776.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -683.75K shares derived: sum of 2 quarters · filed 2023-03-22 | -483.75K shares derived: sum of 3 quarters · filed 2023-03-22 | 15.85K shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 93.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 293.00K shares derived: sum of 2 quarters · filed 2022-11-14 | 792.60K shares 10-Q · filed 2022-11-14 | 1.95M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 200.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 699.60K shares 10-Q · filed 2022-08-15 | 1.86M shares derived: sum of 3 quarters · filed 2022-08-15 | 1.86M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 499.60K shares 10-Q · filed 2022-05-13 | 1.66M shares derived: sum of 2 quarters · filed 2022-05-13 | 1.66M shares derived: sum of 3 quarters · filed 2022-05-13 | 1.72M shares derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-12-31 | 1.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 1.16M shares derived: sum of 2 quarters · filed 2022-03-17 | 1.22M shares derived: sum of 3 quarters · filed 2022-03-17 | 1.22M shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 59.82K shares derived: sum of 2 quarters · filed 2021-11-12 | 59.82K shares 10-Q · filed 2021-11-12 | 59.82K shares derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-06-30 | 59.82K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-23 | 59.82K shares 10-Q · filed 2021-08-23 | 59.82K shares derived: sum of 3 quarters · filed 2022-05-13 | 1.10M shares derived: sum of 4 quarters · filed 2022-05-13 |
| 2021-03-31 | 0.00 shares 10-Q · filed 2022-05-13 | 0.00 shares derived: sum of 2 quarters · filed 2022-05-13 | 1.04M shares derived: sum of 3 quarters · filed 2022-05-13 | 1.69M shares derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | 1.04M shares derived: sum of 2 quarters · filed 2021-03-22 | 1.69M shares derived: sum of 3 quarters · filed 2021-03-22 | 1.69M shares 10-K · filed 2021-03-22 |
| 2020-09-30 | 1.04M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 1.69M shares derived: sum of 2 quarters · filed 2020-11-10 | 1.69M shares 10-Q · filed 2020-11-10 | 1.69M shares derived: sum of 4 quarters · filed 2021-05-14 |
| 2020-06-30 | 648.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | 648.72K shares 10-Q · filed 2020-08-13 | 648.72K shares derived: sum of 3 quarters · filed 2021-05-14 | 830.53K shares derived: sum of 4 quarters · filed 2021-05-14 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-14 | 0.00 shares derived: sum of 2 quarters · filed 2021-05-14 | 181.80K shares derived: sum of 3 quarters · filed 2021-05-14 | -571.82K shares derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | 181.80K shares derived: sum of 2 quarters · filed 2020-03-27 | -571.82K shares derived: sum of 3 quarters · filed 2020-03-27 | 228.18K shares 10-K · filed 2020-03-27 |
| 2019-09-30 | 181.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -571.82K shares derived: sum of 2 quarters · filed 2019-11-14 | 228.18K shares 10-Q · filed 2019-11-14 | 228.18K shares derived: sum of 4 quarters · filed 2019-11-14 |
| 2019-06-30 | -753.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | 46.38K shares 10-Q · filed 2019-08-14 | 46.38K shares derived: sum of 3 quarters · filed 2019-08-14 | 535.02K shares derived: sum of 4 quarters · filed 2019-08-14 |
| 2019-03-31 | 800.00K shares 10-Q · filed 2019-05-14 | 800.00K shares derived: sum of 2 quarters · filed 2019-05-14 | 1.29M shares derived: sum of 3 quarters · filed 2019-05-14 | 1.29M shares derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | 488.64K shares derived: sum of 2 quarters · filed 2019-03-22 | 488.64K shares derived: sum of 3 quarters · filed 2019-08-14 | 488.64K shares 10-K · filed 2019-03-22 |
| 2018-09-30 | 488.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | 488.64K shares derived: sum of 2 quarters · filed 2019-08-14 | 488.64K shares 10-Q · filed 2018-11-14 | 688.64K shares derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | 0.00 shares 10-Q · filed 2019-08-14 | 200.00K shares derived: sum of 3 quarters · filed 2019-08-14 | 213.57K shares derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-14 | 200.00K shares derived: sum of 2 quarters · filed 2019-05-14 | 213.57K shares derived: sum of 3 quarters · filed 2019-05-14 | 246.98K shares derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | 200.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | 213.57K shares derived: sum of 2 quarters · filed 2018-04-02 | 246.98K shares derived: sum of 3 quarters · filed 2018-04-02 | 246.98K shares 10-K · filed 2018-04-02 |
| 2017-09-30 | 13.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | 46.98K shares derived: sum of 2 quarters · filed 2017-11-08 | 46.98K shares 10-Q · filed 2017-11-08 | -5.19M shares derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-06-30 | 33.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | 33.41K shares 10-Q · filed 2017-08-08 | -5.20M shares derived: sum of 3 quarters · filed 2018-05-15 | -3.34M shares derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-15 | -5.24M shares derived: sum of 2 quarters · filed 2018-05-15 | -3.37M shares derived: sum of 3 quarters · filed 2018-05-15 | |
| 2016-12-31 | -5.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-23 | -3.37M shares derived: sum of 2 quarters · filed 2017-03-23 | 436.35K shares 10-K · filed 2017-03-23 | |
| 2016-09-30 | 1.86M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | 5.67M shares 10-Q · filed 2016-11-08 | ||
| 2016-06-30 | 3.81M shares 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |